Director Dealings / Market Share Purchase

RNS Number : 6411C
Oxford Biomedica PLC
23 January 2018
 

 

 

 

 

 

 

Director Dealings / Market Share Purchase

 

Oxford, UK - 23 January 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, discloses that Dr Lorenzo Tallarigo, Chairman of the Group, on Monday 22 January 2017 acquired ordinary shares in the Group as set out below under the market share purchase agreement outlined in the Group's announcement on 15 December 2015.

 

Under the market share purchase agreement, one-third of Dr Tallarigo's fees as Chairman, after tax, are to be used to purchase shares in Oxford BioMedica PLC on a monthly basis at the prevailing market price.

 

 

 

 

 

 

Interest after purchase

Director / PDMR

Title

Price per share (p)

Number of Ordinary Shares acquired

Number of Ordinary Shares

% of total

issued share capital

Dr Lorenzo Tallarigo

Chairman

11.1p

23,941

2,197,028

0.07%

 

The issued share capital of the Group is 3,107,704,224 ordinary 1p shares.                   

 

 

 

-Ends-

 

For further information, please contact:

 

 

Oxford BioMedica plc:

John Dawson,  Chief Executive Officer

Stuart Paynter, Chief Financial Officer

 

Tel: +44 (0)1865 783 000

 

Financial and corporate communications enquiries:

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton

 

 

Tel: +44 (0)20 3709 5700

 

Notes for editors

 

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Orchard Therapeutics and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 300 people. Further information is available at www.oxfordbiomedica.co.uk.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHUOUKRWKAAURR
UK 100

Latest directors dealings